Answers are grounded in this paper and cite their sources.
In vitro study reveals that nicotinamide mononucleotide reduces melanin production by downregulating tyrosinase in B16F10 cells, indicating its potential for treating skin hyperpigmentation.
Skin hyperpigmentation caused by excessive melanin production has led to increasing interest in the development of effective anti-melanogenic agents. In this study, the anti-melanogenic effects and underlying mechanisms of nicotinamide mononucleotide (NMN) were investigated using α-MSH-induced B16F10 melanoma cells. NMN maintained over 80% cell viability at concentrations below 0.5% and significantly reduced α-MSH-induced melanin accumulation and melanin content. In addition, in situ tyrosinase assay demonstrated that NMN effectively suppressed intracellular melanogenesis. However, NMN did not exhibit direct inhibitory activity against mushroom tyrosinase. Molecular docking analysis further revealed that NMN did not directly interact with the catalytic copper-binding site of tyrosinase. Furthermore, tyrosinase zymography and Western blot analyses demonstrated that NMN suppressed melanogenesis primarily through downregulation of tyrosinase protein expression rather than direct inhibition of tyrosinase catalytic activity. Collectively, these findings suggest that NMN suppresses melanogenesis through regulation of melanogenic signaling pathways, indicating its potential utility for hyperpigmentation-related applications.
No takes yet. Share an insight, caveat, or question.
Byeon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: